Anaemia frequently develops in patients with chronic kidney disease (CKD) as the kidneys' ability to produce erythropoietin diminishes. Historically, treatment has relied on replacing this hormone with injectable agents like recombinant human erythropoietin (rhEPO).
This report delivers a targeted analysis of the anaemia treatment landscape in chronic kidney disease (CKD) within Japan, one of the world's most mature nephrology markets and an early adopter of a class of newer oral medications, HIF prolyl hydroxylase inhibitors (HIF-PHIs). Leveraging tracked market data between 2020-2022, this analysis provides evidence-based insights into treatment dynamics across dialysis and non-dialysis segments, and the competitive positioning and ongoing impact of HIF-PHIs following their launch vs traditional rhEPO.
As Japan was the first major market to adopt HIF-PHIs - with roxadustat approval in September 2019 - this report provides a strategic reference point for assessing how these therapies gained traction and what dynamics drove early prescriber behaviour. The definitive case study for de-risking the launch of novel therapies in a mature market.
- Analysis of market structure and segmentation with a focus on high-volume treaters
- Shifting prescribing trends following new therapy class entrants in an established marketplace
- Identification of patient typologies receiving different HIF-PHIs and their distinguishing clinical characteristics
- Exploration of evolving treatment paradigms in dialysis and non-dialysis-dependent patients
- Highlight unmet needs and opportunity zones for your portfolio
- Insights from one consistent, long-established, and robust data source
- Physician-stated and real-world patient findings blended for a holistic view
- Curated by Ipsos' dedicated metabolic disease experts
Sample excerpt from report
- 25 slides
- Data collection timeframe: Q4 2020, Q4 2021, Q4 2022
- Data source: Ipsos Anaemia in CKD Therapy Monitor
- Respondent type: HCPs, patient record forms
- Regions shown: Japan